An algorithmic approach to pharmacoeconomic analyses
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20254168Keywords:
Pharmacoeconomics, Cost-effectiveness analysis, Cost-utility analysisAbstract
Pharmacoeconomics is defined as the description and analysis of costs of drug therapy to health care systems and society. There are various methods used, such as cost-minimization (CMA), cost-effectiveness (CEA), cost-utility (CUA) and cost-benefit analyses (CBA). Others include willingness-to-pay (WTP) and incremental net benefit (INB) analysis. However, there is lack of knowledge in the proper application of these in a coordinated fashion. The aim is to create an algorithm for health-care professionals in deciding appropriate treatment in a pharmacoeconomic perspective when multiple treatment options are available, ensuring safe and effective health-care services within limited resources. For this we reviewed various literature on pharmacoeconomics and compiled various analytical methods being used, along with their pros and cons, including when they can be applied and not. We used all this information to prepare the algorithm which goes as follows. Step 1: for the given patient condition, find the minimum effectiveness of treatment required and list out the health interventions which can provide it along with their costs, benefits and utility. Step 2: conduct INB analysis using WTP method to rule out those which the patient cannot afford. Step 3: among others, conduct CUA followed by CBA, CEA and CMA in this order. Step 4: the treatment option which doesn’t get ruled out at the end of these steps should be considered. If sufficient data is available (which is an important limitation), this algorithm can serve as a powerful tool in optimizing health-care interventions, at least in selective health-care setups.
Metrics
References
Rascati KL Introduction. Essentials of Pharmacoeconomics. Philadelphia, PA: Lippincott Williams and Wilkins. 2013;2:1-5.
Robinson R. Cost-effectiveness analysis. BMJ. 1993;307(6907):793-5. DOI: https://doi.org/10.1136/bmj.307.6907.793
Bang H, Zhao H. Average cost-effectiveness ratio with censored data. J Biopharm Stat. 2012;22(2):401-15. DOI: https://doi.org/10.1080/10543406.2010.544437
Rascati KL Cost-Utility Analysis. Essentials of Pharmacoeconomics. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins. 2013;72-4.
Robinson R. Cost-benefit analysis. BMJ. 1993;307(6909):924-6. DOI: https://doi.org/10.1136/bmj.307.6909.924
Rascati KL. Cost-Benefit Analysis. Essentials of Pharmacoeconomics. Philadelphia, PA: Lippincott Williams and Wilkins. 2013;2:112-3.
Pradelli L, Wertheimer A. Pharmacoeconomics: Principles and Practice. Torino, Italy: SEEd. 2012;1:120.
Rascati KL. Cost-Effectiveness Analysis. Essentials of Pharmacoeconomics. Philadelphia, PA: Lippincott Williams and Wilkins. 2013;2:50-3.
Naithani N, Sinha S, Misra P, Vasudevan B, Sahu R. Precision medicine: Concept and tools. Med J Armed Forces India. 2021;77(3):249-57. DOI: https://doi.org/10.1016/j.mjafi.2021.06.021
Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1-10. DOI: https://doi.org/10.3904/kjim.2009.24.1.1
Aneesh TP, Sonal SM, Jose A, Chandran L, Zachariah SM. Pharmacogenomics: the right drug to the right person. J Clin Med Res. 2009;1(4):191-4.
Reynolds DJ, Aronson JK. ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements. BMJ. 1993;306(6869):48-51. DOI: https://doi.org/10.1136/bmj.306.6869.48
Rascati KL. Cost-Benefit Analysis. Essentials of Pharmacoeconomics. Philadelphia, PA: Lippincott Williams and Wilkins. 2013;2:109-11.
Shah A, Patel C, Shah P, Patel J, Sojitra B, Pandya S, et al. An Analysis of the Cost Variation Among Different Antimicrobial Agents: The Indian Scenario. Cureus. 2024;16(7):e64538. DOI: https://doi.org/10.7759/cureus.64538
Ray A, Najmi A, Khandelwal G, Sadasivam B. A Cost Variation Analysis of Drugs Available in the Indian Market for the Management of Thromboembolic Disorders. Cureus. 2020;12(5):e7964. DOI: https://doi.org/10.7759/cureus.7964
Bruhn WE, Fracica EA, Makary MA. Group Purchasing Organizations, Health Care Costs, and Drug Shortages. JAMA. 2018;320(18):1859-60. DOI: https://doi.org/10.1001/jama.2018.13604
Hernandez I, San-Juan-Rodriguez A, Good CB, Gellad WF. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018. JAMA. 2020;323(9):854-62. DOI: https://doi.org/10.1001/jama.2020.1012
Rascati KL. Cost-Utility Analysis. Essentials of Pharmacoeconomics. Philadelphia, PA: Lippincott Williams and Wilkins. 2013;2:75-8.
Prieto L, Sacristán JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003;1:80. DOI: https://doi.org/10.1186/1477-7525-1-80
Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5-21. DOI: https://doi.org/10.1093/bmb/ldq033
Rascati KL. Cost-Benefit Analysis. Essentials of Pharmacoeconomics. Philadelphia, PA: Lippincott Williams and Wilkins. 2013;2:105-6.
Hollman C, Paulden M, Pechlivanoglou P, McCabe C. A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models. Pharmacoeconomics. 2017;35(8):817-30. DOI: https://doi.org/10.1007/s40273-017-0510-8
Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm. 1992;49(7):1741-7. DOI: https://doi.org/10.1093/ajhp/49.7.1741
Sanchez LA. Pharmacoeconomics and formulary decision making. Pharmacoeconomics. 1996;9:16-25. DOI: https://doi.org/10.2165/00019053-199600091-00005